

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)



(10) International Publication Number
WO 2021/133907 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) A61K 38/17 (2006.01)

A61P 25/28 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2020/066831

(22) International Filing Date:

23 December 2020 (23.12.2020)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/953,099 23 December 2019 (23.12.2019) US

63/091,819 14 October 2020 (14.10.2020) US

(71) Applicant: DENALI THERAPEUTICS INC. [US/US];

161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(72) Inventors: CHERF, Gerald Maxwell; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

KANNAN, Gunasekaran; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

LEXA, Katrina W.; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

LOW, Ray L.Y.; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

PROROK, Rachel; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

SRIVASTAVA, Ankit; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: HAO, Joe C. et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: PROGRANULIN VARIANTS

(57) Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.

